Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network
罕见疾病临床研究网络高苯丙氨酸血症疾病联盟
基本信息
- 批准号:10481857
- 负责人:
- 金额:$ 153.63万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-16 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Access to InformationAdolescenceAdolescentAdultAffectAgeAnxietyAttentional deficitBasic ScienceBehavioralBiological MarkersBiopterinBloodBrainCase SeriesChildChronicClinicalClinical ResearchClinical Trials NetworkCognitiveConsumptionDataDefectDiagnosisDietDiet therapyDietary ProteinsDiseaseEarly DiagnosisEmploymentEnzymesEsthesiaEvaluationExecutive DysfunctionExhibitsFamilyFosteringFunctional disorderFundingFutureGoalsHealthHereditary DiseaseHyperphenylalaninaemiasImpairmentInborn Errors of MetabolismIncidenceIndividualInfantInheritedInternationalInterpersonal RelationsLearning DisabilitiesLifeLinkLongevityLongitudinal StudiesLongitudinal observational studyLongterm Follow-upMaternal PhenylketonuriaMeasuresMedicalMental DepressionMolecular ChaperonesNamesNeonatal ScreeningNeurologicNeuropsychologyNormal RangeOutcomePatient Outcomes AssessmentsPatientsPersonsPhenylalaninePhenylalanine HydroxylasePhenylketonuriasPregnancyProteinsProviderPublicationsPublishingQuality of lifeRare DiseasesRecyclingReportingResearchResearch PersonnelResearch ProposalsResourcesScientistScreening ResultSiblingsSiteSupplementationSyndromeTeratogensTherapeutic AgentsTherapeutic EffectTimeTrainingTreatment ProtocolsUnited States National Institutes of HealthValidationVisionbrain fogcognitive disabilitycohortdesigndietaryeducation resourcesexecutive functionexperiencefetalfunctional outcomesimprovedinattentionmotor impairmentneuropsychiatrynext generationnovelnovel therapeuticspatient advocacy grouppreventpsychiatric symptomrare conditionsevere intellectual disabilitystandard of caresymposiumtetrahydrobiopterintreatment researchweb sitewhite matterwhite matter damage
项目摘要
1. PROJECT SUMMARY – OVERALL
We propose to construct a multicenter collaborative consortium to be part of the Rare Diseases Clinical
Research Network (RDCRN) that will be dedicated to clinical research on inborn errors of metabolism causing
hyperphenylalaninemia (elevated blood phenylalanine), one of the most common abnormalities detected
through newborn screening. Hyperphenylalaninemia may be caused by phenylalanine hydroxylase (PAH)
deficiency (also colloquially known as phenylketonuria (PKU)), by disorders of biopterin synthesis and recycling,
or by a recently described deficiency of a PAH co-chaperone protein named DNAJC12. Newborn screening
and dietary phenylalanine restriction, initiated in the US beginning in the 1960s for PAH deficiency, has been
convincingly shown through collaborative study to prevent severe cognitive disability in infants and children,
but currently, there are no large longitudinal studies of adolescents or adults with PAH deficiency and no long
term follow up data at all on children or adults with biopterin synthesis or recycling defects nor of DNAJC12
deficiency. Clinical experience and many small published case series demonstrate that non-adherence to
dietary therapy in adolescence and adulthood is commonplace. Chronically elevated blood phenylalanine is
associated with a high incidence of executive dysfunction, anxiety, depression, and with impaired educational
and vocational potential. Some adults suffer irreversible white matter damage and motor impairment due to
chronically elevated blood phenylalanine. Elevated blood phenylalanine during pregnancy is severely
teratogenic leading to the so-called maternal PKU syndrome. Novel therapies that are not strictly dependent
upon dietary phenylalanine restriction are highly desired, but the appropriate treatment goals are yet poorly
understood. What concentration of blood phenylalanine is necessary to guarantee optimal outcome continues
to be debated and other biomarkers that correlate with outcome continue to be sought. The objectives of this
project are to comprehensively and longitudinally evaluate the health, neurologic, cognitive, neuropsychiatric,
patient-reported, and quality-of-life outcomes in a large cohort of individuals of all ages with PAH deficiency,
with biopterin synthesis or recycling disorders, or with DNAJC12 deficiency and to explore correlations
between outcomes and blood phenylalanine or other biomarkers. The consortium will also form a network of
clinical trial sites prepared to readily participate in the evaluation of novel therapeutic agents designed to treat
hyperphenylalaninemia disorders. The results of this study will allow refinement and improvement of current
and future therapies for the most common inborn error of metabolism and the rarer conditions associated with
hyperphenylalaninemia.
1. 项目概要——总体
我们建议建立一个多中心合作联盟,作为罕见疾病临床的一部分
研究网络(RDCRN)将致力于针对先天性代谢缺陷引起的临床研究
高苯丙氨酸血症(血液苯丙氨酸升高),最常见的异常之一
通过新生儿筛查。高苯丙氨酸血症可能由苯丙氨酸羟化酶(PAH)引起
生物蝶呤合成和循环障碍导致的缺乏症(俗称苯丙酮尿症 (PKU)),
或者最近描述的一种名为 DNAJC12 的 PAH 共伴侣蛋白的缺陷。新生儿筛查
美国从 20 世纪 60 年代开始针对 PAH 缺乏症开始实行膳食苯丙氨酸限制,
通过合作研究令人信服地证明可以预防婴儿和儿童的严重认知障碍,
但目前,还没有针对患有 PAH 缺乏症的青少年或成人进行大型纵向研究,也没有长期研究
有关生物蝶呤合成或回收缺陷或 DNAJC12 的儿童或成人的长期随访数据
不足。临床经验和许多已发表的小型病例系列表明,不遵守
饮食疗法在青春期和成年期很常见。血苯丙氨酸长期升高是
与执行功能障碍、焦虑、抑郁以及教育受损的高发生率相关
和职业潜力。一些成年人由于以下原因遭受不可逆的白质损伤和运动障碍:
血液苯丙氨酸长期升高。怀孕期间血苯丙氨酸升高严重
致畸,导致所谓的母体 PKU 综合征。不严格依赖的新疗法
非常希望限制膳食苯丙氨酸,但适当的治疗目标尚不清楚
明白了。需要多少浓度的血液苯丙氨酸才能保证持续获得最佳结果
有待争论,并继续寻找与结果相关的其他生物标志物。本次活动的目标
项目旨在全面、纵向地评估健康、神经学、认知、神经精神、
患者报告的以及一大群患有多环芳烃缺乏症的各个年龄段个体的生活质量结果,
与生物蝶呤合成或循环障碍,或与 DNAJC12 缺陷相关,并探索相关性
结果与血液苯丙氨酸或其他生物标志物之间的关系。该联盟还将组建一个网络
准备好参与评估旨在治疗的新型治疗药物的临床试验场所
高苯丙氨酸血症疾病。这项研究的结果将有助于完善和改进当前的
以及针对最常见的先天性代谢错误和与代谢相关的罕见疾病的未来治疗方法
高苯丙氨酸血症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cary O. Harding其他文献
Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study
- DOI:
10.1016/j.gim.2025.101459 - 发表时间:
2025-08-01 - 期刊:
- 影响因子:6.200
- 作者:
Cary O. Harding;Kaleigh Bulloch Whitehall;Joshua Lilienstein;Ogun Sazova;Kristin Lindstrom;Drew G. Levy;Barbara K. Burton - 通讯作者:
Barbara K. Burton
404. Therapeutic Correction of PKU in a Mouse Model by Ectopic Expression of PAH and Its BH4- Cofactor Genes in Skeletal Muscle by a Recombinant Triple-Cistronic AAV2-Based Pseudotype 1 Vector
- DOI:
10.1016/j.ymthe.2006.08.467 - 发表时间:
2006-01-01 - 期刊:
- 影响因子:
- 作者:
Zhaobing Ding;Cary O. Harding;Alexandre Rebuffat;Lina Elzaouk;JonA. Wolff;Beat Thony - 通讯作者:
Beat Thony
Myoadenylate deaminase deficiency caused by alternative splicing due to a novel intronic mutation in the <em>AMPD1</em> gene
- DOI:
10.1016/j.ymgme.2005.06.002 - 发表时间:
2005-09-01 - 期刊:
- 影响因子:
- 作者:
Paul J. Isackson;Heather Bujnicki;Cary O. Harding;Georgirene D. Vladutiu - 通讯作者:
Georgirene D. Vladutiu
219. Persistent Correction of Hyperphenylalaninemia Following Liver-Directed, rAAV2/8-Mediated Gene Therapy for Murine Phenylketonuria (PKU)
- DOI:
10.1016/j.ymthe.2006.08.244 - 发表时间:
2006-01-01 - 期刊:
- 影响因子:
- 作者:
Cary O. Harding;Melanie B. Gillingham;Elizabeth Daghighi;Andrew Bird;Dwight D. Koeberl - 通讯作者:
Dwight D. Koeberl
Intelligence quotient scores among early-treated phenylketonuria patients: results from a systematic literature review
- DOI:
10.1186/s13023-025-03830-0 - 发表时间:
2025-06-20 - 期刊:
- 影响因子:3.500
- 作者:
Fiona O’Sullivan;Ioannis Tomazos;Francjan J. van Spronsen;Shelagh M. Szabo;Maanasa Venkataraman;Lavanya Huria;Neil Smith;Lachlan Molony;Kim Ingalls;Kathleen Somera-Molina;Rongrong Zhang;Cary O. Harding - 通讯作者:
Cary O. Harding
Cary O. Harding的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cary O. Harding', 18)}}的其他基金
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia
沙丙蝶呤反应性高苯丙氨酸血症中苯丙氨酸代谢的定量测量
- 批准号:
10701016 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network
罕见疾病临床研究网络高苯丙氨酸血症疾病联盟
- 批准号:
10260442 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network
罕见疾病临床研究网络高苯丙氨酸血症疾病联盟
- 批准号:
10019398 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
Hyperphenylalaninemia Disorders Consortium of the Rare Disease Clinical Research Network
罕见疾病临床研究网络高苯丙氨酸血症疾病联盟
- 批准号:
10701011 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia
沙丙蝶呤反应性高苯丙氨酸血症中苯丙氨酸代谢的定量测量
- 批准号:
10481862 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
Quantitative Measurement of Phenylalanine Metabolism in Sapropterin-Responsive Hyperphenylalaninemia
沙丙蝶呤反应性高苯丙氨酸血症中苯丙氨酸代谢的定量测量
- 批准号:
10019407 - 财政年份:2019
- 资助金额:
$ 153.63万 - 项目类别:
相似海外基金
Identification of Prospective Predictors of Alcohol Initiation During Early Adolescence
青春期早期饮酒的前瞻性预测因素的鉴定
- 批准号:
10823917 - 财政年份:2024
- 资助金额:
$ 153.63万 - 项目类别:
Socio-Emotional Characteristics in Early Childhood and Offending Behaviour in Adolescence
幼儿期的社会情感特征和青春期的犯罪行为
- 批准号:
ES/Z502601/1 - 财政年份:2024
- 资助金额:
$ 153.63万 - 项目类别:
Fellowship
Cognitive and non-cognitive abilities and career development during adolescence and adult development: from the perspective of genetic and environmental structure
青春期和成人发展期间的认知和非认知能力与职业发展:从遗传和环境结构的角度
- 批准号:
23K02900 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Reasoning about Spatial Relations and Distributions: Supporting STEM Learning in Early Adolescence
空间关系和分布的推理:支持青春期早期的 STEM 学习
- 批准号:
2300937 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Continuing Grant
Does social motivation in adolescence differentially predict the impact of childhood threat exposure on developing suicidal thoughts and behaviors
青春期的社会动机是否可以差异预测童年威胁暴露对自杀想法和行为的影响
- 批准号:
10785373 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Mapping the Neurobiological Risks and Consequences of Alcohol Use in Adolescence and Across the Lifespan
绘制青春期和整个生命周期饮酒的神经生物学风险和后果
- 批准号:
10733406 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
The Role of Sleep in the Relationships Among Adverse Childhood Experiences, Mental Health Symptoms, and Persistent/Recurrent Pain during Adolescence
睡眠在不良童年经历、心理健康症状和青春期持续/复发性疼痛之间关系中的作用
- 批准号:
10676403 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Thalamo-prefrontal circuit maturation during adolescence
丘脑-前额叶回路在青春期成熟
- 批准号:
10585031 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Interdisciplinary Perspectives on the Politics of Adolescence and Democracy
青少年政治与民主的跨学科视角
- 批准号:
EP/X026825/1 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Research Grant
An Empirical Study on the Influence of Socioeconomic Status in Adolescence on Exercise Habits in Adulthood
青春期社会经济地位对成年期运动习惯影响的实证研究
- 批准号:
23K16734 - 财政年份:2023
- 资助金额:
$ 153.63万 - 项目类别:
Grant-in-Aid for Early-Career Scientists